Early Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with endometrial cancer (uterine cancer), including specific types such as endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma.
• People who have had surgery that included removal of the uterus, both fallopian tubes and ovaries, and an assessment of the pelvic lymph nodes (with or without assessment of lymph nodes near the main abdominal artery).
• People whose cancer has been surgically staged as FIGO (2009) stage IIIA or IIIC1.
• People who agree to a specific type of tumour genetic testing called MSK-IMPACT Part A (with encouragement to also consent to Part C).
• People aged 18 years or older.
• People who are in reasonably good general health, as measured by standard medical scoring tools (Karnofsky Performance Status of 70 or above, or ECOG score of 0 or 1).
• People with no more than mild nerve-related symptoms affecting sensation or movement (grade 1 or lower).
• People who had no visible cancer remaining after surgery.
• People who have not previously received radiation therapy or chemotherapy for endometrial cancer.
• People who have no active infection requiring antibiotics, except for a straightforward urinary tract infection.
• People whose blood test results before starting treatment show that their blood counts, liver function, and kidney function are within acceptable ranges as defined by the trial.
• People who are enrolling within 12 weeks of the date of their surgery.
• People who have had or currently have another cancer, where that cancer or its treatment is unlikely to affect the safety or results of this trial (confirm with trial site).
• People who are not breastfeeding and who agree not to breastfeed during the study or for 150 days after the last dose of treatment.

Who may not be able to join:

• People whose endometrial cancer has a specific genetic change called a POLE mutation.
• People whose endometrial cancer has been found to have a condition called mismatch repair deficiency, or a related feature called microsatellite instability-high (MSI-H), based on specific laboratory tests.
• People with active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
• People with certain serious or uncontrolled health conditions that could affect safety or trial results, including but not limited to: uncontrolled heart rhythm problems, a heart attack within the past 90 days, chronic obstructive pulmonary disease, uncontrolled seizure disorder, unstable spinal cord compression, or a condition called superior vena cava syndrome (confirm with trial site for other conditions).
• People who have previously received radiation therapy to the pelvis.
• People who have previously received radiation covering more than 20% of the bone marrow within the past 2 weeks, or any radiation within 1 week before starting the trial treatment.
• People who have had, or currently have, an abnormal passage (fistula) between the bladder and vagina, the bowel and vagina, or the colon and vagina.
• People with a blood disorder or abnormality that the treating doctor considers a reason to avoid radiation therapy.

Important: Always verify eligibility with the trial site directly before applying.